(WASHINGTON) FDA REPORT: Approval of the first drug for ‘Alzheimer’s Disease’ in 20yrs that shows substantial evidence that it reducesamyloid beta plaques in the brain” and that this “is reasonably likely to predict important benefits to patients #AceHealthDesk report | Ace News Services

#AceNewsReport – June.09: Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms:

Source: (WASHINGTON) FDA REPORT: Approval of the first drug for ‘Alzheimer’s Disease’ in 20yrs that shows substantial evidence that it reducesamyloid beta plaques in the brain” and that this “is reasonably likely to predict important benefits to patients #AceHealthDesk report | Ace News Services